Article
Chemistry, Applied
Hatice Gamze Sogukomerogullari, Tugba Taskin Tok, Serhan Urus, Mehmet Sonmez
Summary: This study synthesized and characterized four SNS pincer-type thioether containing Pd (II) complexes, which were then used as catalysts in the synthesis of vitamin K-3 from 2-methyl naphthalene. The L2-Pd (II) and L3-Pd (II) complexes exhibited the best catalytic activity, with in silico studies confirming their superior chemical reactivity.
APPLIED ORGANOMETALLIC CHEMISTRY
(2022)
Article
Medicine, General & Internal
A. Bardia, S. A. Hurvitz, S. M. Tolaney, D. Loirat, K. Punie, M. Oliveira, A. Brufsky, S. D. Sardesai, K. Kalinsky, A. B. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortes, J. O'Shaughnessy, V Dieras, C. Ferrario, P. Schmid, L. A. Carey, L. Gianni, M. J. Piccart, S. Loibl, D. M. Goldenberg, Q. Hong, M. S. Olivo, L. M. Itri, H. S. Rugo
Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Immunology
Jie Li, Dejiao He, Sicheng Li, Jun Xiao, Zhanyong Zhu
Summary: This review discusses the role of ferroptosis in TNBC and explores its potential value in the progression, diagnosis, and treatment of TNBC.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
George Sflomos, Nora Schaumann, Matthias Christgen, Henriette Christgen, Stephan Bartels, Hans Kreipe, Laura Battista, Cathrin Brisken
Summary: Invasive lobular carcinoma (ILC) is a common subtype of breast cancer, often diagnosed at advanced stages. Up to 30% of ILC patients experience relapse, posing a treatment challenge. To address this, we have created a new in vivo model for ILC by grafting triple-negative human cancer cells into mice, which accurately recapitulates the different stages of ILC and provides a valuable tool for preclinical studies on TN ILC.
Article
Biochemistry & Molecular Biology
Ebtihal H. Mustafa, Geraldine Laven-Law, Zoya Kikhtyak, Van Nguyen, Simak Ali, Alex A. Pace, Richard Iggo, Alemwork Kebede, Ben Noll, Shudong Wang, Jean M. Winter, Amy R. Dwyer, Wayne D. Tilley, Theresa E. Hickey
Summary: Targeting transcription via CDK9 could be a potential therapeutic strategy for TNBC. Preclinical studies showed that a selective CDK9 inhibitor, CDDD11-8, effectively inhibited proliferation, induced cell cycle arrest, and increased apoptosis of TNBC cells in vitro and in vivo, without apparent toxicity to normal tissues.
Review
Oncology
Yun Li, Huajun Zhang, Yulia Merkher, Lin Chen, Na Liu, Sergey Leonov, Yongheng Chen
Summary: Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer with a poor prognosis. Current treatment options are limited, but targeted therapies focusing on DNA repair pathways, androgen receptor signaling pathways, kinases, and immunotherapy have shown promise.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Chemistry, Physical
Xiangli Liu, Michael H. Abraham, William E. Acree
Summary: By using literature values for the solubility of vitamin K3 in organic solvents, Abraham descriptors for vitamin K3 were obtained. When combined with established equations, these descriptors can predict important properties of vitamin K3, such as vapor pressure, heat of sublimation, and various partitions in different phases.
JOURNAL OF MOLECULAR LIQUIDS
(2021)
Review
Pharmacology & Pharmacy
Jun Zhang, Yu Xia, Xiaomei Zhou, Honghao Yu, Yufang Tan, Yaying Du, Qi Zhang, Yiping Wu
Summary: Triple-negative breast cancer is a highly malignant subtype of breast cancer with aggressive behaviors. It is associated with poor clinical outcomes, early recurrence, and a higher likelihood of visceral metastases compared to other types of breast cancer. Personalized or combined therapies based on molecular heterogeneity are showing promising results in treating triple-negative breast cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
P. Schmid, J. Cortes, R. Dent, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y. H. Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P. A. Fasching, F. Cardoso, J. Andersen, D. Patt, M. Danso, M. Ferreira, M-A Mouret-Reynier, S-A Im, J-H Ahn, M. Gion, S. Baron-Hay, J-F Boileau, Y. Ding, K. Tryfonidis, G. Aktan, V Karantza, J. O'Shaughnessy
Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Dnyaneshwar Kalyane, Suryanarayana Polaka, Nupur Vasdev, Rakesh Kumar Tekade
Summary: This study reports a novel gold nanocomposite (T)GNC-DOX, targeted for triple-negative breast cancer (TNBC) treatment using pulsatile chemo-photothermal therapy. The developed (T)GNC-DOX demonstrated efficient drug release, potent photothermal response, and stability, making it suitable for chemo-photothermal therapy in the tumor microenvironment. The results showed selective localization of (T)GNC-DOX in cancer cells, leading to significant cytotoxic effect, and induction of cell apoptosis through photothermal ablation and ROS generation.
Article
Biochemistry & Molecular Biology
Eriko Katsuta, Kazuaki Takabe, Marija Vujcic, Philip A. Gottlieb, Tao Dai, Arnaldo Mercado-Perez, Arthur Beyder, Qingfei Wang, Mateusz Opyrchal
Summary: High expression of PIEZO2 in breast cancer, particularly in triple-negative breast cancer (TNBC), is associated with worse clinical outcomes. Activation of PIEZO2 leads to increased cell motility and invasive phenotypes, as well as the upregulation of epithelial-mesenchymal transition (EMT)-related genes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Chrysoula Tsirigoti, Mohamad Moustafa Ali, Varun Maturi, Carl-Henrik Heldin, Aristidis Moustakas
Summary: The transcription factor SNAI1 plays an important role in breast cancer by regulating cellular transformation, differentiation and migration. Loss of SNAI1 function may lead to changes in the phenotype of breast cancer cells and an increase in differentiation potential, possibly through the dual transcriptional action of FOXA1 and AR.
CELL DEATH & DISEASE
(2022)
Review
Oncology
Hongnan Mo, Binghe Xu
Summary: Triple-negative breast cancer is the most aggressive subtype of breast cancer, where chemotherapy shows activity in some patients but drug resistance remains a challenge. Significant progress in genetic analysis has led to the identification of novel targets and improved precision in therapeutic interventions, advancing treatment strategies.
FRONTIERS OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Alyssa Vito, Stephanie Rathmann, Natalie Mercanti, Nader El-Sayes, Karen Mossman, John Valliant
Summary: The study investigated the combination of radionuclide therapy and immunotherapy for breast cancer, finding that neither monotherapy improved therapeutic outcomes, but the combination significantly extended overall survival and reduced necrotic tissue within the tumor, as well as suppressed inflammatory cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)